Biota Holdings is suing GlaxoSmithKline over the drug giant's alleged failure to support the smaller company's flu drug, Relenza. GlaxoSmithKline holds the license to develop and commercialize the drug, which Biota claims would have captured 40 percent market share with proper support. Relenza currently has about 5 percent of the flu market. That alleged lack of market support cost Biota up to $325 million, the company claims.
- read this story from Asia Pulse for more